A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)
Latest Information Update: 01 Nov 2023
At a glance
- Drugs Zelicapavir (Primary)
- Indications Respiratory syncytial virus infections; Respiratory tract infections
- Focus Therapeutic Use
- Acronyms RSVP
- Sponsors Enanta Pharmaceuticals
Most Recent Events
- 18 May 2022 According to an Enanta Pharmaceuticals media release, data from this trial will be presented at a future medical meeting or in a peer-reviewed publication.
- 18 May 2022 Primary endpoint ( Effect of EDP-938 compared to placebo on RSV infection clinical symptoms measured as the total symptom score (TSS) area under the curve (AUC) from Day 1 through Day 14) has not been met as per Enanta Pharmaceuticals Media Release
- 18 May 2022 Results published in the Enanta Pharmaceuticals Media Release